JP2015512447A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512447A5 JP2015512447A5 JP2015504647A JP2015504647A JP2015512447A5 JP 2015512447 A5 JP2015512447 A5 JP 2015512447A5 JP 2015504647 A JP2015504647 A JP 2015504647A JP 2015504647 A JP2015504647 A JP 2015504647A JP 2015512447 A5 JP2015512447 A5 JP 2015512447A5
- Authority
- JP
- Japan
- Prior art keywords
- tyrosine kinase
- inhibitor
- fgfr
- pharmaceutically acceptable
- met
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261619502P | 2012-04-03 | 2012-04-03 | |
| US61/619,502 | 2012-04-03 | ||
| PCT/US2013/034759 WO2013151913A1 (en) | 2012-04-03 | 2013-04-01 | Tyrosine kinase inhibitor combinations and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015512447A JP2015512447A (ja) | 2015-04-27 |
| JP2015512447A5 true JP2015512447A5 (https=) | 2016-05-19 |
Family
ID=48184451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015504647A Pending JP2015512447A (ja) | 2012-04-03 | 2013-04-01 | チロシンキナーゼ阻害薬の組合せおよびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150051210A1 (https=) |
| EP (1) | EP2833917A1 (https=) |
| JP (1) | JP2015512447A (https=) |
| KR (1) | KR20140146086A (https=) |
| CN (1) | CN104244982A (https=) |
| AU (1) | AU2013243737B2 (https=) |
| CA (1) | CA2866321A1 (https=) |
| IN (1) | IN2014DN07410A (https=) |
| MX (1) | MX2014011987A (https=) |
| RU (1) | RU2014143213A (https=) |
| WO (1) | WO2013151913A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6752715B2 (ja) | 2014-03-26 | 2020-09-09 | アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | 組合せ |
| ES2831416T3 (es) * | 2014-07-31 | 2021-06-08 | Novartis Ag | Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR |
| ES2887148T3 (es) | 2015-03-25 | 2021-12-21 | Nat Cancer Ct | Agente terapéutico contra el cáncer de vías biliares |
| US12414945B2 (en) | 2015-12-17 | 2025-09-16 | Eisai R&D Management Co., Ltd. | Therapeutic agent for breast cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| DE102005038537A1 (de) | 2005-08-16 | 2007-02-22 | Merck Patent Gmbh | 1-Acyldihydropyrazolderivate |
| HUE030390T2 (en) | 2005-12-21 | 2017-05-29 | Janssen Pharmaceutica Nv | Triazolopyridazines as tyrosine kinase modulators |
| NL2000613C2 (nl) | 2006-05-11 | 2007-11-20 | Pfizer Prod Inc | Triazoolpyrazinederivaten. |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| AU2007309149C1 (en) | 2006-10-23 | 2013-04-04 | Sgx Pharmaceuticals, Inc. | Bicyclic triazoles as protein kinase modulators |
| ME02372B (me) * | 2006-11-22 | 2016-06-20 | Incyte Holdings Corp | Imidazotriazini i imidazopiramidini kao inhibitori kinaze |
| JP4994044B2 (ja) * | 2007-01-05 | 2012-08-08 | シェブロンジャパン株式会社 | 潤滑油組成物 |
| CA2683559C (en) * | 2007-04-13 | 2019-09-24 | Dana Farber Cancer Institute, Inc. | Methods for treating cancer resistant to erbb therapeutics |
| CA2720888A1 (en) * | 2008-04-29 | 2009-11-05 | Novartis Ag | Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods |
| EP2288383A1 (en) * | 2008-05-14 | 2011-03-02 | Amgen, Inc | Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer |
| JP5781510B2 (ja) | 2009-08-12 | 2015-09-24 | ノバルティス アーゲー | ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用 |
| EP2621483A1 (en) * | 2010-09-27 | 2013-08-07 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
-
2013
- 2013-04-01 MX MX2014011987A patent/MX2014011987A/es unknown
- 2013-04-01 AU AU2013243737A patent/AU2013243737B2/en not_active Ceased
- 2013-04-01 EP EP13718671.4A patent/EP2833917A1/en not_active Withdrawn
- 2013-04-01 CN CN201380018928.6A patent/CN104244982A/zh active Pending
- 2013-04-01 US US14/388,251 patent/US20150051210A1/en not_active Abandoned
- 2013-04-01 IN IN7410DEN2014 patent/IN2014DN07410A/en unknown
- 2013-04-01 KR KR1020147027542A patent/KR20140146086A/ko not_active Withdrawn
- 2013-04-01 RU RU2014143213A patent/RU2014143213A/ru not_active Application Discontinuation
- 2013-04-01 WO PCT/US2013/034759 patent/WO2013151913A1/en not_active Ceased
- 2013-04-01 JP JP2015504647A patent/JP2015512447A/ja active Pending
- 2013-04-01 CA CA2866321A patent/CA2866321A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8518930B2 (en) | Therapeutic combination comprising a CDKS inhibitor and an antineoplastic agent | |
| MX2024010140A (es) | Nuevos metodos. | |
| WO2015048662A3 (en) | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | |
| CY1125488T1 (el) | Παραγωγα πυριδινης και θεραπευτικες χρησεις αυτων ως αναστολεις trpc6 | |
| FI3157527T3 (fi) | Ezh2-inhibiittoreita lymfoman hoitoon | |
| PH12013501594A1 (en) | Substituted indazole derivatives active as kinase inhibitors | |
| JP2019516711A5 (https=) | ||
| BR112015015477A2 (pt) | derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk | |
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| EA201170249A1 (ru) | 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ | |
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| JP2012236857A5 (https=) | ||
| JP2015524472A5 (https=) | ||
| HRP20160562T1 (hr) | Derivat pirimidina kao inhibitori fak | |
| EA201490016A1 (ru) | Комбинация панобиностата и руксолитинаба при лечении рака, такого как миелопролиферативное новообразование | |
| EA201592254A1 (ru) | Производные пиразолопирролидин-4-она и их применение при лечении заболевания | |
| HRP20120918T1 (hr) | Aminopirazolski spoj | |
| GEAP202416013A (en) | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors | |
| ATE453646T1 (de) | 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren | |
| FI3840753T3 (fi) | Migalastaatti käytettäväksi fabryn taudin hoitomenetelmissä potilailla joilla on gla-geenin mutaatio | |
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| EA201290694A1 (ru) | Сульфонамидные производные 3,4-диарилпиразолов в качестве ингибиторов протеинкиназы | |
| EA201270651A1 (ru) | Карбоксамиды пиридинон гидроксициклопентила: ингибиторы вич интегразы и области терапевтического применения | |
| JP2015512447A5 (https=) | ||
| HRP20191019T1 (hr) | Kombinacijska terapija konjugatom protutijela i lijeka anti-her2 i inhibitorom bcl-2 |